PO.TB04.03 · 肿瘤生物学
用于评估免疫检查点抑制剂的高通量3D肿瘤-免疫共培养平台
A high-throughput 3D tumor-immune co-culture platform for evaluating immune checkpoint inhibitors
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
免疫检查点抑制剂(ICI)的开发需要能够准确反映人类肿瘤细胞与免疫细胞之间相互作用的临床前模型。传统的2D系统缺乏结构和免疫学相关性,而动物模型往往无法再现人类检查点调控。因此,亟需生理学相关且可扩展的体外平台,以提高早期ICI评估的预测能力。为满足这一需求,我们开发了一种高通量3D肿瘤-免疫共培养平台,用于模拟检查点活性并量化免疫介导的肿瘤反应。肿瘤微组织以Akura™384形式生成并经处理以诱导抑制性配体表达,同时通过特定的共刺激通路刺激人类免疫细胞以诱导检查点受体表达。建立共培养体系后,我们施加参考ICI或对照抗体,并采用多种检测方法评估反应。凋亡性肿瘤细胞死亡通过Caspase-3/7 Glo®进行量化,肿瘤完整性通过基于荧光的活力检测进行监测。免疫活化通过多重细胞因子和细胞溶解介质分析进行评估。采用高内涵成像可视化免疫-肿瘤相互作用、球体结构变化和免疫浸润深度,并辅以自动化分割工作流程。流式细胞术分析提供了关于免疫活化和检查点受体调控的表型信息。为将该平台从淋巴系检查点扩展开来,我们建立了一个髓系模块,将pH敏感染料标记的肿瘤球体与荧光标记的巨噬细胞共培养,以量化吞噬摄取。检查点阻断在上述各项读数中均增强了免疫效应功能。我们观察到caspase-3/7活化增加以及肿瘤球体活力下降。细胞因子分析显示炎性和细胞溶解介质释放升高,成像显示免疫细胞深入渗透至3D结构中。流式细胞术证实了与活化相关的免疫表型,而髓系模块则显示巨噬细胞-肿瘤结合和吞噬作用增强。总之,该3D共培养平台提供了一个生理学相关、稳健且可扩展的系统,用于表征人类肿瘤-免疫相互作用并评估ICI活性。它将微组织工程与多参数功能和表型检测相结合,为更具预测性的临床前评估以及加速下一代ICI和生物类似药的开发提供了一种转化方法。
查看英文原文 English abstract
The development of immune checkpoint inhibitors (ICIs) requires preclinical models that accurately reflect interactions between human tumor and immune cells. Conventional 2D systems lack architectural and immunological relevance, and animal models often fail to capture human checkpoint regulation. There is therefore a strong need for physiologically relevant and scalable in vitro platforms to improve the predictive power of early-stage ICI evaluation.To address this need, we developed a high-throughput 3D tumor-immune co-culture platform to model checkpoint activity and quantify immune-mediated tumor responses. Tumor microtissues were generated in the Akura™384 format and treated to induce inhibitory ligand expression, while human immune cells were stimulated through defined co-stimulatory pathways to induce checkpoint receptor expression. After establishing the co-cultures, we applied reference ICIs or control antibodies and assessed responses using multiple assays. Apoptotic tumor cell death was quantified using Caspase-3/7 Glo®, and tumor integrity was monitored through fluorescence-based viability assays. Immune activation was evaluated using multiplex cytokine and cytolytic mediator profiling. High-content imaging was used to visualize immune-tumor interactions, spheroid structural changes, and immune infiltration depth, supported by automated segmentation workflows. Flow cytometry analysis provided phenotypic information on immune activation and checkpoint receptor modulation. To extend the platform beyond lymphoid checkpoints, we established a myeloid module in which pH-sensitive dye-labeled tumor spheroids were co-cultured with fluorescent macrophages to quantify phagocytic uptake.Checkpoint blockade enhanced immune effector function across these readouts. We observed increased caspase-3/7 activation and reduced viability of tumor spheroids. Cytokine profiling revealed elevated inflammatory and cytolytic mediator release, and imaging demonstrated deep immune penetration into the 3D architecture. Flow cytometry confirmed activation-associated immune phenotypes, while the myeloid module showed increased macrophage-tumor engagement and phagocytosis.In summary, this 3D co-culture platform provides a physiologically relevant, robust, and scalable system for characterizing human tumor-immune interactions and evaluating ICI activity. Its integration of microtissue engineering with multiparametric functional and phenotypic assays offered a translational approach for more predictive preclinical assessment and accelerated development of next-generation ICIs and biosimilars.
利益披露 Disclosure
L. Ligeon, None..
T. Gamma, None..
Z. Kotkowska, None..
C. Veser, None..
I. Agarkova, None..
S. Grepper, None..
M. Nag-LAL, None.